Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory CultureGlobeNewsWire • 05/20/20
Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen ProgramsGlobeNewsWire • 05/13/20
Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer TreatmentGlobeNewsWire • 05/07/20
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020GlobeNewsWire • 01/22/20
Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in WomenGlobeNewsWire • 12/19/19
Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth ConferenceGlobeNewsWire • 10/23/19
Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal TechnologyGlobeNewsWire • 10/16/19
Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral EndoxifenGlobeNewsWire • 09/30/19
Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment ConferenceGlobeNewsWire • 09/06/19
Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen TabletGlobeNewsWire • 09/03/19
Atossa Genetics: Expect More Near-Term Positive Catalysts After Continued FDA Approval For One PatientSeeking Alpha • 03/18/19